Peptonic Medical AB (publ) (“Peptonic” or the “Company”) has today submitted a request to the Uppsala District Court to extend the ongoing corporate reconstruction by three months, until 15 December 2025. The extension is supported by the Company’s reconstruction trustee.

Since the start of the reconstruction, the Company has implemented several important measures to strengthen its financial position. During the period April–August, sales exceeded the forecast published in June, with an increase of approximately SEK 1.4 million in revenue (+16%). The full-year forecast remains in line with previous estimates, and the Company confirms that EBITDA break-even is expected to be reached in November.

The Company’s principal shareholder, Maida Vale Capital AB, has provided the Company with brid

See Full Page